Authors: Andrea Piccin Chiara Maria Grana Giovanni Negri Irene Pusceddu Giovanni Paganelli Sergio Cortelazzo
Publish Date: 2011/04/21
Volume: 91, Issue: 2, Pages: 299-300
Abstract
Peptide receptor radionuclide therapy PRRT with 90YDOTATOC or 177LuDOTATATE has demonstrated its efficacy in the treatment of neuroendocrine and somatostatinreceptor expressing tumours 1 2 Several clinical trials have confirmed that adverse effects are represented by possible renal impairment 3 and low but not absent haematological toxicityHe was a 50yearold man with a past medical history of alcoholism oesophagitis arterial hypertension thalassemia βminor and deep venous thrombosis of left popliteal vein He was also a heavy smoker In November 2005 following repeated episodes of upper abdominal pain he underwent a thoracic and abdominal CTscan which showed a pancreatic lesion of 20 mm and another lesion in the Vater papilla of 30 mm in size An Octreoscan® showed high uptake on the
Keywords: